跳至主要内容
临床试验/NCT01274741
NCT01274741已完成不适用

Pilot Study of an Integrated Exposure-Based Model for Posttraumatic Stress Disorder and Substance Use Disorder

VA Boston Healthcare System2 个研究点 分布在 1 个国家目标入组 52 人开始时间: 2011年1月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
52
试验地点
2
主要终点
Change in PTSD Checklist total score - from baseline through end of treatment and 3-month followup

研究概览

简要总结

This study compares Creating Change, a new past-focused behavioral therapy for posttraumatic stress disorder (PTSD)/substance use disorder (SUD), to Seeking Safety, an evidence-based present-focused behavioral therapy for PTSD/SUD.

详细描述

This study evaluates a new behavioral therapy model, Creating Change (CC) for PTSD/SUD. CC helps clients explore the past as a step in their recovery process. It has major public health relevance in that it is a low-cost, flexible model designed for all trauma and substance abuse types, both genders, and all clinical settings. It has particular relevance for VA in that many veterans suffer from PTSD and SUD. The new model demonstrated positive results in two pilot studies.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Meet Diagnostic and Statistical Manual (DSM-IV) criteria for current PTSD and current substance use disorder
  • Have used a substance in the 60 days prior to intake
  • Outpatient
  • Plan to stay in Boston for the next 6 months
  • If on psychiatric medication, are on a stable regimen for at least 4 weeks prior to participation in the study
  • Have a stable mailing address and live nearby enough to come to VA Boston for treatment
  • Able to sign informed consent
  • Willing to participate in all assessments and urine testing
  • Willing to provide a release of information for study staff to contact treaters as needed for clinical concerns

排除标准

  • Any current acute medical condition that would either interfere with the patient's ability to attend treatment, or would be of such severity as to affect the patient's psychological functioning
  • Current bipolar I disorder, schizophrenia or other psychotic disorders, mental retardation, or organic mental disorder
  • Any obvious clinical sign that the patient is not sufficiently stable to participate in the treatment, or notification by the patient's primary providers that participation would be contraindicated
  • Dangerousness that would present a threat to staff or patients (e.g., history of assault within the past 6 months)
  • The patient is mandated to treatment

结局指标

主要结局

Change in PTSD Checklist total score - from baseline through end of treatment and 3-month followup

时间窗: Baseline, end of treatment (approximately 4 months from baseline), and 3-month followup

PTSD symptoms assessed via self-report measure

Change in Addiction Severity Index alcohol composite score - from baseline through end of treatment and 3-month followup

时间窗: Baseline, end of treatment (approximately 4 months from baseline), and 3-month followup

Alcohol use and associated problems as measured by blinded-interviewer measure Composite. These outcome variables will be measured at baseline, end of treatment and 3-month followup.

Change in diagnosis of PTSD on the MINI Neuropsychiatric Interview - from baseline through end of treatment and 3-month followup

时间窗: Baseline, end of treatment (approximately 4 months from baseline), and 3-month followup

PTSD diagnosis as assessed by a trained interviewer

Change in Addiction Severity Index drug composite score - from baseline through end of treatment and 3-month followup

时间窗: Baseline, end of treatment (approximately 4 months from baseline), and 3-month followup

Drug use and associated problems as measured by blinded-interviewer measure Composite. These outcome variables will be measured at baseline, end of treatment and 3-month followup. Urinanlysis/breathalyzer will be obtained to verify ASI self-report.

次要结局

  • Change in Quality of Life Satisfaction & Enjoyment Scale - from baseline through end of treatment and 3-month followup(Baseline, end of treatment (approximately 4 months from baseline), and 3-month followup)
  • Change in Brief Symptom Inventory-Global Severity Index - from baseline through end of treatment and 3-month followup(Baseline, end of treatment (approximately 4 months from baseline), and 3-month followup)
  • Change in World Assumptions Scale - from baseline through end of treatment and 3-month followup(Baseline, end of treatment (approximately 4 months from baseline), and 3-month followup)
  • Change in Trauma Related Guilt Inventory - from baseline through end of treatment and 3-month followup(Baseline, end of treatment (approximately 4 months from baseline), and 3-month followup)
  • Change in Beliefs About Substance Use - from baseline through end of treatment and 3-month followup(Baseline, end of treatment (approximately 4 months from baseline), and 3-month followup)
  • Change in General Self-Efficacy - from baseline through end of treatment and 3-month followup: Self-report measure(Baseline, end of treatment (approximately 4 months from baseline), and 3-month followup)
  • Change in Coping Self-Efficacy Scale - from baseline through end of treatment and 3-month followup(Baseline, end of treatment (approximately 4 months from baseline), and 3-month followup)

研究者

申办方类型
Fed
责任方
Principal Investigator
主要研究者

Karen Krinsley

PTSD Section Chief

VA Boston Healthcare System

研究点 (2)

Loading locations...

相似试验